Immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder which presents with isolated thrombocytopenia and risk of hemorrhage. While most children with ITP promptly recover with or without drug therapy, ITP is persistent or chronic in others. When needed, how to select second-line therapies is not clear. ICON1, conducted within the Pediatric ITP Consortium of North America (ICON), is a prospective, observational, longitudinal cohort study of 120 children from 21 centers starting second-line treatments for ITP which examined treatment decisions. Treating physicians reported reasons for selecting therapies, ranking the top three. In a propensity weighted model, the most important factors were patient/parental preference (53%) and treatment-related factors: side effect profile (58%), long-term toxicity (54%), ease of administration (46%), possibility of remission (45%), and perceived efficacy (30%). Physician, health system, and clinical factors rarely influenced decision-making. Patient/parent preferences were selected as reasons more often in chronic ITP (85.7%) than in newly diagnosed (0%) or persistent ITP (14.3%, P 5 .003). Splenectomy and rituximab were chosen for the possibility of inducing long-term remission (P < .001). Oral agents, such as eltrombopag and immunosuppressants, were chosen for ease of administration and expected adherence (P < .001). Physicians chose rituximab in patients with lower expected adherence (P 5 .017). Treatment choice showed some physician and treatment center bias. This study illustrates the complexity and many factors involved in decision-making in selecting second-line ITP treatments, given the absence of comparative trials. It highlights shared decision-making and the need for well-conducted, comparative effectiveness studies to allow for informed discussion between patients and clinicians.
| I N TR ODU C TI ON
Immune thrombocytopenia (ITP) is an uncommon hematologic condition during childhood. Despite presenting with severe thrombocytopenia, only 0.4%-0.6% of affected children will have intracranial hemorrhage (ICH) and <3% will have other severe (non-ICH) bleeding at diagnosis. 1, 2 The majority (70%-80%) will experience complete resolution of their disorder within 12 months from diagnosis. 3, 4 Many such children can be safely managed initially with close observation, with the decision to initiate front-line therapy with corticosteroids, anti-D immunoglobulin, or intravenous immunoglobulin (IVIG) based on signs or symptoms of mucocutaneous bleeding or bleeding risk. 5, 6 There has been extensive controversy regarding how to manage newly diagnosed children with ITP. The indications, timing, and choice of second-line treatment in children with ITP, when needed, are more complex and highly variable among treating physicians. 7 Among many options are splenectomy, rituximab, oral immunosuppressive agents, thrombopoietin receptor agonists (TPO-RA), and intermittent first-line treatments (e.g., IVIG or corticosteroids). Each differs in potential short and long-term efficacy and side effect profiles. Additional considerations include patient age, different routes of administration, dietary considerations, monitoring, and costs, which in turn influence patient, family, and physician preference. Therefore, selection of a specific second-line treatment for a child with ITP is complex and ideally would be individualized.
In shared decision-making, health care decisions are made together by the patient and/or caregiver along with the medical provider. The goal is to fully engage in an informed consent model of care by improving communication between providers and their patients or caregivers.
One recent study suggested a lack of shared decision-making in the care of children with ITP. 8 Focus groups have revealed that parents of children with ITP commonly have feelings of anxiety and confusion and feel they had little choice in the decision for treatment. Physicians also have their own biases, which influence their decision-making. [8] [9] [10] A few studies have attempted to address the importance of decision modeling and shared decision-making for first-line ITP therapy, 7 but factors involved in decision-making around second-line therapies for children with ITP have not been studied.
ICON1 was subsequently designed as a prospective, observational, longitudinal cohort study of children starting second-line treatments for ITP to be conducted by the Pediatric ITP Consortium of North America (ICON). 11 In this report, the factors physicians prioritize when selecting second-line treatments for individual patients were explored.
| M E TH ODS

| ICON1 study design
Prior to study initiation, a focus group was convened to determine which factors would be ascertained in assessment of physician decision-making. This focus group, consisting of 13 investigators with expertise in ITP, designed a conceptual model (Supporting Information Figure S1 ), which was then used in ICON1. The process by which the conceptual model was derived is described in the Supporting were grouped for comparison and included 6-mercaptopurine (n 5 13), azathioprine (n 5 1), mycophenolate (n 5 3), and sirolimus (n 5 2). To better understand reasons for treatment choice, physicians were asked to select and rank the top three reasons for their treatment choice. A weighted summary of reasons for treatment choice was created by giving the top reason a weight of three, the second reason a weight of two, and the third reason a weight of one. These weights were used to determine the most important reasons for treatment choice. Distribution of treatment choice between centers was restricted to five centers with adequately large sample sizes (n 8 patients) and was compared using Fisher's exact test.
| RE S U L TS
| ICON1 demographics
One hundred twenty patients were enrolled in the study (Table 1) ; the majority (85%, n 5 102) had primary ITP. 13 The types of secondary ITP included: Evans syndrome (n 5 9), underlying immunodeficiencies (n 5 5), rheumatologic conditions (n 5 3), and inflammatory bowel disease (n 5 1). The median age was 11.7 years (range 1.2-17.8 years).
The majority of children had chronic ITP (n 5 64, 53%) but a significant proportion were newly diagnosed (n 5 19, 16%). Children had received a median of 3 prior treatments (range 0-8) with 47 (39%) patients having received at least one prior second-line treatment, including rituximab (n 5 12, 10%), romiplostim (n 5 11, 9%), eltrombopag (n 5 10, 8%), 6-mercaptopurine/azathioprine (n 5 6, 5%), and/or splenectomy (n 5 3, 3%). Two patients had no prior treatments and were monitored with observation only.
Patients were treated by physicians who were a median of 8 years 
| Overall reasons for selecting treatments
In the nonweighted analysis, the most important factors guiding treatment decisions were patient and parental preference (53%) and treatment-related factors, including the side effect profile (58%), longterm toxicity (54%), ease of administration (46%), possibility of remission (45%), and efficacy (30% In the propensity weighted analysis, the most commonly selected factors included possibility of long-term remission, parental and patient preference, side effect profile, and ease of administration ( Figure 1 
| Reasons for selecting specific treatments
Certain treatments tended to be favored for specific reasons ( Figure 2) .
A significant determinant of choosing splenectomy or rituximab (P < .001) was the possibility of long-term remission. This reason was Among the most frequent reasons for favoring an individual treatment, the specific treatment related factors were major determinants (Table 2 ). For rituximab, 93% of physicians endorsed at least one treatment factor; for oral immunosuppressants, romiplostim, and eltrombopag, 100% of physicians endorsed at least one treatment factor.
Although treatment related factors were the major determinants, the specifics of the factors differed among them. For romiplostim, the side effect profile (68%) was the most important treatment factor. For rituximab, the possibility of cure was a major treatment factor (91%), whereas for oral immunosuppressant agents and eltrombopag, ease of administration (84% and 95%, respectively) was most important. The oral treatments, eltrombopag and oral immunosuppressants, were also selected for similar patient-centered reasons, including patient adherence and preference.
In all patients undergoing splenectomy (n 5 4), this option was selected both due to the possibility of long-term remission and patient or provider preference. Those patients who underwent splenectomy had a median age of 16.2 years (range 15-17 years) and 75% had chronic ITP.
These patients had received a median of 1 prior second-line treatments (range 1-2), which included rituximab (n 5 3) and eltrombopag (n 5 1).
One splenectomized patient had no prior second-line treatments.
| Physician/patient factors and treatment choice
There was no relationship between the age of the patient and the treatment selected (P 5 .20). The experience of the physician, in terms of the number of years in practice, also did not correlate with the second-line treatment chosen (P 5 .25).
There was a tendency for individual physicians to select certain treatments. When restricting the analysis to the five highest enrolling centers (n 5 61; range 8-17 patients per center), there was an association between treatment choice and treatment center (P 5 .008). In particular, rituximab was selected for at least half the patients at two centers, while romiplostim was selected for more than half of the patients at two other centers. Individual treatments were most often chosen for similar reasons.
For example, clinicians chose splenectomy and rituximab because of the possibility of long-term remission desired by the patient and family.
The most robust data regarding long term remission is available for splenectomy, a longstanding historical treatment for ITP, for which there is some confidence in its efficacy and long-term remission rates. [14] [15] [16] [17] Nevertheless, only 6 of the 120 patients in this study had already undergone splenectomy at the time of enrollment and just 4 additional patients underwent the procedure during the study. This presumably represents the trend in both children and adults to defer or avoid splenectomy in favor of medical therapies, given the concerns about long-term sequelae of splenectomy. 18, 19 Rituximab, on the other hand, is a relatively newer treatment for ITP, and the long-term remission data are not as robust. 20 While initial response rates were encouraging with rituximab, long-term remission at 5 years now appears to be much lower (20%-30%) and consistent with expected spontaneous remission rates. 20 Based on the ICON1 data, the perceived long term efficacy of rituximab among pediatric hematologists and patients may be higher than that demonstrated in clinical trials.
Eltrombopag was approved for children 1 year of age in 2015, and romiplostim, although used off-label, is not yet approved for use in pediatric ITP. Most patients in this study were enrolled during 2013 to FIG URE 2 Ranked reasons for physician choice by second-line therapy. Individual therapies were examined and weighted scores were assigned to reasons for physician choice. Scores in this figure are re-scaled so that equally long bars indicate that the reason was equally ranked for each treatment. Reasons that were less important are excluded from the figure 2015 before eltrombopag was FDA approved for children. As expected, long-term remission was not prioritized with regard to selecting TPO-RA therapy. Data about potential efficacy and side effects with these agents is evolving. [21] [22] [23] [24] However, the TPO-RAs were also selected for a perceived reduction of toxicity, presumably because they avoid immunosuppression. While there has been some evolution of data over the course of this study, in general, physician practice did not change and prescribing patterns were similar over time.
Practice varied by center, which may reflect the practice of single physicians at these centers, physicians' perception of efficacy and potential side effects of individual treatments, or dissemination of novel information about current treatments for ITP. Although physicians reported that they did not select treatments based on their own comfort level, these center specific practices suggest that physician factors and institutional biases do influence treatment selection. While parent and patient preference is a primary reason for selecting a treatment, this is often strongly influenced by the treating physician's experience and the manner in which information is presented to families. 25, 26 The lack of comparative effectiveness studies for evidence-based decisionmaking increases the potential for physician and center-specific biases. This study illustrates the complexity of decision making in the absence of comparative trials. Perhaps even more importantly, it also emphasizes the need for ongoing clinical research to better define populations of ITP patients most likely to benefit from specific interventions and to compare treatments in these populations. This study also underscores the need for a shared decision-making model to ensure a comprehensive consideration of all factors important to both physicians and their patients and families. Fully incorporating and individually prioritizing the key factors for a given patient requires extensive discussion to fully inform and engage the patient in the treatment decision. Finally, by describing our collective experience, the authors anticipate that this study may serve as a basis for the design of clinical trials which will adequately address knowledge gaps and inform patient and clinician decision-making.
